ROTHBLATT MARTINE A sold $5.2M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $543.95 ($540.24–$546.00, $5.17M total) across 7 trades on 2026-06-23 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing confirms the sale size (~$5.17M), execution date (2026-06-23), and that it was conducted under a pre-arranged 10b5-1 plan, which generally lowers interpretive value for near-term fundamentals.
Market read
Provides a fresh, auditable insider-selling datapoint for UTHR, but without accompanying fundamental news.
What to watch
Traders may over-weight insider sales; the key is whether there are concurrent fundamental catalysts (earnings, guidance, trial updates) not present in this filing.
Background
This is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR) by its Chairperson & CEO, Martine Rothblatt.
Ticker impact
United Therapeutics CEO/Chair sold 9,500 shares in open-market transactions totaling about $5.17M under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any reaction is more about sentiment than fundamentals.
Form 4 provides a concrete datapoint (size, dates, price range) yet the presence of a pre-arranged 10b5-1 plan typically dampens interpretability versus discretionary selling.
Market effects
Minimal; this is company-specific insider activity with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider sale disclosure.
- insiderROTHBLATT MARTINE A
Chairperson & CEO who sold 9,500 shares in open-market transactions.
